FARMINGTON, CT, USA, August 29, 2022 /EINPresswire.com/ -- ImStem Biotechnology, Inc., a clinical stage biotechnology company focused on human pluripotent stem cell based regenerative cellular therapies to treat serious diseases with high unmet need, announced today that Prof. Rudolf Jaenisch has joined ImStem Biotechnology, Inc., as a Member of its Scientific Advisory Board Rudolf Jaenisch is a Professor of Biology at MIT (spell out) and a founding member of the Whitehead Institute for Biomedical Research. As a pioneer in transgenic science (making mouse models of human disease), he generated the first transgenic mice and used them to study cancer and neurological disease.
FARMINGTON, Conn., Nov. 18, 2021 /PRNewswire/ -- ImStem Biotechnology, Inc. (Farmington CT), a biopharmaceutical company pioneering the development of human embryonic stem cell (ESC) derived mesenchymal stem cells (hES-MSC) through a proprietary method using a trophoblast intermediate stage (termed T-MSC), today announced the dosing of the first US multiple sclerosis patient with its lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA. IMS001 is an investigational, allogeneic cell product to be administered intravenously to patients suffering from MS. We believe this is the first hES-MSC based allogeneic cell therapy accepted for clinical trial by the FDA for patients with MS. The company plans to continue enrollment in a dose-escalating, open-label study to evaluate the safety, tolerability, and exploratory efficacy of single dose of IV IMS001 in subjects with relapsing-remitting, secondary, or primary progressive MS with treatment failure to prior disease modifying treatments (DMTs).
ALAMEDA, Calif. & FARMINGTON, Conn.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing innovative regenerative therapeutics to treat human diseases to increase healthspan and combat the effects of aging, and Imstem Biotechnology, Inc.